Targeting the blood vessels that feed tumours is not the silver bullet once hoped for, but refinements to the strategy may suggest further ways to treat the disease. Erika Check Hayden reports.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 52 print issues and online access
$199.00 per year
only $3.83 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
References
Folkman, J. N. Engl. J. Med. 285, 1182–1186 (1971).
Pàez-Ribes, M. et al. Cancer Cell 15, 220–231 (2009).
Ebos, J. M. L. et al. Cancer Cell 15, 232–239 (2009).
Reynolds, A. R. et al. Nature Med. doi:10.1038/nm.1941 (2009).
Pennacchietti, S. et al. Cancer Cell 3, 347–361 (2003).
Additional information
See Editorial, page 679 .
Related links
Related links
Related links in Nature Research
Nature Reviews Cancer: When good drugs do bad things
Nature Reviews Cancer Focus on Targeting Angiogenesis
Related external links
US National Cancer Institute fact sheet on angiogenesis inhibitors
Rights and permissions
About this article
Cite this article
Hayden, E. Cutting off cancer's supply lines. Nature 458, 686–687 (2009). https://doi.org/10.1038/458686b
Published:
Issue date:
DOI: https://doi.org/10.1038/458686b
